{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:25:48Z","timestamp":1780622748759,"version":"3.54.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian\/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. The objective of this study was to validate this finding at the messenger RNA (mRNA) and protein levels. Quantitative real-time polymerase chain reaction analysis of 126 m\u00fcllerian carcinomas and 23 malignant mesotheliomas showed significantly higher PRAME mRNA expression in the former tumor (P &amp;lt; .001; test sensitivity and specificity, 89% and 91%, respectively). PRAME protein was expressed in 41 of 50 m\u00fcllerian carcinomas and 0 of 30 mesotheliomas using Western blotting (P &amp;lt; .001; test sensitivity and specificity, 82% and 100%, respectively). PRAME levels in m\u00fcllerian carcinoma were unrelated to survival; however, PRAME protein expression was up-regulated in solid metastases compared with primary carcinoma and effusions (P &amp;lt; .001). Our data confirm that PRAME effectively differentiates m\u00fcllerian carcinoma from malignant mesothelioma at the mRNA and protein levels, suggesting a role in the diagnostic workup of serosal cancers.<\/jats:p>","DOI":"10.1309\/ajcpga95kvsaudmf","type":"journal-article","created":{"date-parts":[[2012,1,19]],"date-time":"2012-01-19T00:46:06Z","timestamp":1326933966000},"page":"240-247","source":"Crossref","is-referenced-by-count":18,"title":["PRAME (Preferentially Expressed Antigen of Melanoma) Is a Novel Marker for Differentiating Serous Carcinoma From Malignant Mesothelioma"],"prefix":"10.1093","volume":"137","author":[{"given":"Kjersti","family":"Brenne","sequence":"first","affiliation":[{"name":"1Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag Andr\u00e9","family":"Nymoen","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuven","family":"Reich","sequence":"additional","affiliation":[{"name":"2Institute of Drug Research, School of Pharmacy, Faculty of Medicine, the David R. Bloom Center for Pharmacy, and the Brettler Center for Pharmacology, The Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway"},{"name":"3Faculty of Medicine, University of Oslo, Oslo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,2,1]]},"reference":[{"key":"2023011911094335600_b1-1370240","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1615\/CritRevOncog.v13.i3.10","article-title":"The biological characteristics of cancers involving the serosal cavities","volume":"13","author":"Davidson","year":"2007","journal-title":"Crit Rev Oncog"},{"key":"2023011911094335600_b2-1370240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2303.2010.00829.x","article-title":"The diagnostic and molecular characteristics of malignant mesothelioma and ovarian\/peritoneal serous carcinoma","volume":"22","author":"Davidson","year":"2011","journal-title":"Cytopathology"},{"key":"2023011911094335600_b3-1370240","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1158\/1078-0432.CCR-06-1059","article-title":"Gene expression signatures differentiate ovarian\/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma","volume":"12","author":"Davidson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2023011911094335600_b4-1370240","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"2023011911094335600_b5-1370240","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1158\/0008-5472.CAN-04-4011","article-title":"Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo","volume":"65","author":"Tajeddine","year":"2005","journal-title":"Cancer Res"},{"key":"2023011911094335600_b6-1370240","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.taap.2007.05.019","article-title":"Corepressors of agonist-bound nuclear receptors","volume":"223","author":"Gurevich","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"key":"2023011911094335600_b7-1370240","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/jcp.22417","article-title":"Retinoids regulate stem cell differentiation","volume":"226","author":"Gudas","year":"2011","journal-title":"J Cell Physiol"},{"key":"2023011911094335600_b8-1370240","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"2023011911094335600_b9-1370240","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","article-title":"A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer","volume":"66","author":"Epping","year":"2006","journal-title":"Cancer Res"},{"key":"2023011911094335600_b10-1370240","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","article-title":"Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2\u2032-deoxycytidine","volume":"64","author":"Sigalotti","year":"2004","journal-title":"Cancer Res"},{"key":"2023011911094335600_b11-1370240","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/path.2229","article-title":"Systematic search for the best gene expression markers for melanoma micrometastasis detection","volume":"213","author":"Soikkeli","year":"2007","journal-title":"J Pathol"},{"key":"2023011911094335600_b12-1370240","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1158\/1078-0432.CCR-08-1102","article-title":"Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells","volume":"14","author":"Greiner","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2023011911094335600_b13-1370240","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/1476-4598-9-226","article-title":"Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia","volume":"9","author":"Wadelin","year":"2010","journal-title":"Mol Cancer"},{"key":"2023011911094335600_b14-1370240","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome","volume":"10","author":"Oberthuer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2023011911094335600_b15-1370240","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1593\/neo.06415","article-title":"Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications","volume":"8","author":"Morandi","year":"2006","journal-title":"Neoplasia"},{"key":"2023011911094335600_b16-1370240","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1038\/sj.onc.1207043","article-title":"Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes","volume":"22","author":"Boon","year":"2003","journal-title":"Oncogene"},{"key":"2023011911094335600_b17-1370240","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0002-9440(10)61166-2","article-title":"Gene expression in Wilms\u2019 tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition","volume":"160","author":"Li","year":"2002","journal-title":"Am J Pathol"},{"key":"2023011911094335600_b18-1370240","first-page":"359","article-title":"Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors","volume":"4","author":"Biermann","year":"2007","journal-title":"Cancer Genomics Proteomics"},{"key":"2023011911094335600_b19-1370240","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","article-title":"Prevalence and prognostic and predictive relevance of PRAME in breast cancer","volume":"109","author":"Doolan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2023011911094335600_b20-1370240","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br J Cancer"},{"key":"2023011911094335600_b21-1370240","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-009-0365-6","article-title":"Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach","volume":"119","author":"Sun","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2023011911094335600_b22-1370240","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.bjc.6602779","article-title":"Overexpression of aurora B kinase (AURKB) in primary non\u2013small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability","volume":"93","author":"Smith","year":"2005","journal-title":"Br J Cancer"},{"key":"2023011911094335600_b23-1370240","first-page":"4090","article-title":"Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?","volume":"58","author":"Neumann","year":"1998","journal-title":"Cancer Res"},{"key":"2023011911094335600_b24-1370240","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1097\/01.ju.0000118383.86684.38","article-title":"Simultaneous expression of T-cell activating antigens in renal cell carcinoma: implications for specific immunotherapy","volume":"171","author":"Ringhoffer","year":"2004","journal-title":"J Urol"},{"key":"2023011911094335600_b25-1370240","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000070305","article-title":"Expression of cancer\/testis tumor associated antigens in cervical squamous cell carcinoma","volume":"64","author":"Sarcevic","year":"2003","journal-title":"Oncology"},{"key":"2023011911094335600_b26-1370240","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/hed.20380","article-title":"Expression of cancer testis antigens in head and neck squamous cell carcinomas","volume":"28","author":"Figueiredo","year":"2006","journal-title":"Head Neck"},{"key":"2023011911094335600_b27-1370240","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/ijc.25607","article-title":"Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma","volume":"128","author":"Cuffel","year":"2011","journal-title":"Int J Cancer"},{"key":"2023011911094335600_b28-1370240","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/gcc.20465","article-title":"Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies","volume":"46","author":"Schenk","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"2023011911094335600_b29-1370240","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ejca.2006.06.026","article-title":"Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors","volume":"42","author":"Partheen","year":"2006","journal-title":"Eur J Cancer"},{"key":"2023011911094335600_b30-1370240","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/ijc.23758","article-title":"Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas","volume":"123","author":"Partheen","year":"2008","journal-title":"Int J Cancer"},{"key":"2023011911094335600_b31-1370240","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/1471-2407-9-336","article-title":"External validation suggests integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas","volume":"9","author":"Partheen","year":"2009","journal-title":"BMC Cancer"},{"key":"2023011911094335600_b32-1370240","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase reaction (RQ-PCR): a Europe Against Cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"2023011911094335600_b33-1370240","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/133.8.1317","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group","volume":"133","author":"Husain","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"2023011911094335600_b34-1370240","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.humpath.2009.02.013","article-title":"Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions","volume":"40","author":"Yuan","year":"2009","journal-title":"Hum Pathol"},{"key":"2023011911094335600_b35-1370240","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.06.003","article-title":"SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions [published online ahead of print August 18, 2011]","author":"Bock","journal-title":"Hum Pathol"},{"key":"2023011911094335600_b36-1370240","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.05.023","article-title":"Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival [published online ahead of print August 18, 2011]","author":"Brenne","journal-title":"Hum Pathol"},{"key":"2023011911094335600_b37-1370240","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/PAS.0b013e3181b6bde3","article-title":"Tenascin-X is a novel diagnostic marker of malignant mesothelioma","volume":"33","author":"Yuan","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"2023011911094335600_b38-1370240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2303.2010.00757.x","article-title":"PINCH-2 expression in cancers involving serosal effusions using quantitative PCR","volume":"22","author":"Yuan","year":"2011","journal-title":"Cytopathology"},{"key":"2023011911094335600_b39-1370240","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/156800907780006904","article-title":"Anatomic site\u2013related expression of cancer-associated molecules in ovarian carcinoma","volume":"7","author":"Davidson","year":"2007","journal-title":"Curr Cancer Drug Targets"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/137\/2\/240\/48771205\/ajcp_137_2_240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/137\/2\/240\/48771205\/ajcp_137_2_240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T11:52:30Z","timestamp":1674129150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/137\/2\/240\/1760732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,1]]},"published-print":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcpga95kvsaudmf","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,2,1]]},"published":{"date-parts":[[2012,2,1]]}}}